SEC’s Biannual Earnings Proposal Sparks Debate Amid Investor Concerns

Paul Atkins leans back in his chair, the familiar skyline of the Financial District framed in the window behind him. The SEC chairman has spent a career navigating the complex interplay between market efficiency and investor protection. His latest proposal, however, has struck a nerve he admits is raw. The idea seems simple enough: let companies, particularly young, pre-revenue firms, file financial reports twice a year instead of every quarter. To him, it’s a matter of tailoring a one-size-fits-all system. To nearly everyone else who has written in, it’s a dangerous step backward.

“What do I tell a pre-revenue biotech company that’s gone public and is waiting for the FDA to say yay or nay?” Atkins posed the question during a recent discussion, his tone more weary than defensive. “They go for sometimes years without showing any revenue. So what am I supposed to tell them? You just have to file a 10Q anyway?” For him, the proposal is about proportionality. It’s about freeing a nascent pharmaceutical firm from the considerable expense and administrative burden of quarterly filings when its financial story—losses funding research—is essentially unchanged for quarters on end. He argues the rule would allow such a company to “make it more responsible, basically, for their investors and the expenses that they have with respect to their disclosures.”

But the public response has been a tidal wave of dissent. The SEC’s comment period closed with a staggering 200,000 submissions. A tracker maintained by an accounting professor at Ohio State University revealed that 99.5% of those letters opposed the change. The backlash isn’t coming from fringe voices. It’s led by asset managers and retail investor advocacy groups, the very constituents who rely most heavily on consistent, transparent data. Their fear, as voiced in countless comments, is that semiannual reporting would create a shroud, making it easier for companies to conceal financial rot until it’s too late. They worry it would widen the information asymmetry that already favors corporate insiders, creating ripe opportunities for insider trading and leaving Main Street investors at a distinct disadvantage.

Atkins hears the criticism, but believes much of it stems from a fundamental misunderstanding. “This proposal is giving the company the option,” he emphasizes. It doesn’t mandate biannual reports; it simply adds it to the menu alongside quarterly and more frequent disclosures. A company could still host its quarterly earnings call and issue guidance, he notes, just without the full formal 10-Q filing. “When people say, oh, this could be less transparent or whatnot, we have a one-size-fits-all rule right now,” he counters, suggesting the current rigidity may itself be a form of inefficiency.

The political reality, however, may ultimately matter more than the philosophical debate. The SEC is currently operating with just three commissioners, all of whom are Republican. This lopsided composition makes the passage of the proposal, despite the public outcry, a likely outcome. It’s a scenario that highlights how administrative rulemaking can sometimes move on a track parallel to but detached from overwhelming stakeholder sentiment.

From my desk a few blocks from the SEC’s headquarters, this situation feels like a classic Wall Street dilemma packaged in a regulatory wrapper. It pits the allure of flexibility and cost-saving for companies against the bedrock principle of market transparency. The biotech example is compelling, but it’s the exception, not the rule. For every research-driven startup, there are dozens of established firms where quarterly discipline acts as a crucial check on management and a vital source of information for price discovery.

The profound uniformity of the opposition is what gives me pause. In my two decades covering finance, I’ve rarely seen such consensus across the spectrum from large institutional money managers to individual investor advocates. They aren’t arguing over basis points or accounting treatments; they’re defending the fundamental rhythm of the market. That quarterly pulse—for all its imperfections and its tendency to encourage short-term thinking—provides a regular, audited health check. Diluting that rhythm to twice a year introduces a significant lag in the feedback loop between a company’s performance and the market’s awareness of it.

Atkins is right that the rule is optional. But in practice, optionality can create a problematic two-tier system. Companies facing headwinds would have a powerful incentive to retreat to the biannual schedule, effectively going radio silent for six months at a time. That absence of information wouldn’t be interpreted as neutral by the market; it would be seen, rightly or wrongly, as a red flag. It could incentivize exactly the kind of informational arbitrage and hidden risk that critics fear.

The proposal, while framed as modernizing a dated system, risks solving a narrow problem for a small subset of companies by introducing a broader problem of opacity for the entire market. The cost savings for some could very well become an information cost borne by all investors. In an era where trust in financial markets is perpetually fragile, clarity and consistency are currencies more valuable than ever. The SEC’s mandate, at its core, is to protect investors and maintain fair, orderly, and efficient markets. Based on the resounding voice of those investors, this proposal seems to miss the mark on the first objective, potentially undermining the other two in the process. The commission would be wise to listen not just to the logic of flexibility but to the overwhelming empirical feedback from the market itself. Sometimes, the most important data point isn’t on a balance sheet; it’s in the comment box.

• Atkins’ proposal to reduce filing frequency
• Impact on pre-revenue biotech companies
• Public dissent with 99.5% opposition
• Concerns over market transparency
• Potential for insider trading
• Political context of SEC composition